New trial aims to make stem cell transplants safer for blood cancer patients
NCT ID NCT03970096
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing two different methods to reduce graft-versus-host disease (GVHD) in patients with acute leukemia or myelodysplastic syndrome (MDS) who are receiving a donor stem cell transplant. One method removes certain immune cells from the donor cells before transplant, and the other uses a drug after transplant. The goal is to see which approach leads to better survival without severe GVHD or relapse. The study plans to enroll 120 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selective depletion of CD45RA+ naïve T cells or post-transplant cyclophosphamide
- What this could lead to
- If successful, this could lead to safer stem cell transplants with fewer severe side effects, improving survival and quality of life for leukemia and MDS patients.
- What could go wrong
- This is a mid-stage trial with only 120 participants, so results may not apply to everyone. Both strategies have risks, including infection or graft failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?